Compare RCKT & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCKT | TCPC |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.2M | 407.2M |
| IPO Year | N/A | 2006 |
| Metric | RCKT | TCPC |
|---|---|---|
| Price | $4.73 | $3.62 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 14 | 2 |
| Target Price | ★ $29.65 | $3.50 |
| AVG Volume (30 Days) | ★ 2.8M | 1.3M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | ★ 21.92% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $97.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.19 | $3.64 |
| 52 Week High | $8.80 | $8.11 |
| Indicator | RCKT | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 22.18 |
| Support Level | $2.99 | N/A |
| Resistance Level | $5.34 | $5.99 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 47.90 | 2.49 |
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.